A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

October 17, 2021

Study Completion Date

October 17, 2021

Conditions

Severe Hemophilia A

Interventions

DRUG

ADVATE

a single dose.

DRUG

FRSW117

a single dose.

Trial Locations (4)

Jinan central hospital, Jinan

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin

People's Hospital of Zhengzhou, Zhengzhou

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Jiangsu Gensciences lnc.

INDUSTRY